Post Date:
December 29, 2020 Issue Date:
January 16, 2021

Vaccine accounting

Name: WORLD
Price range: $

You have {{ remainingArticles }} free {{ counterWords }} remaining. You've read all of your free articles.

Full access isn’t far.

We can’t release more of our sound journalism without a subscription, but we can make it easy for you to come aboard.

Get started for as low as $3.99 per month.

Current WORLD subscribers can log in to access content. Just go to "SIGN IN" at the top right.

LET'S GO

Already a member? Sign in.

$6.1 billion

The total amount the United States government has agreed to pay pharmaceutical companies Pfizer and Moderna for their COVID-19 vaccines. The government provided Moderna with $955 million for initial development, then bought two 100-million-dose orders for $1.53 billion and $1.68 billion respectively. The government bought 100 million doses from Pfizer for $1.95 billion but provided no initial funding for development.

37,586

The number of participants in Pfizer’s phase 3 vaccine trial.

18,801

The number of Pfizer phase 3 participants who received the vaccine, not a placebo.

30,351

The number of participants in Moderna’s phase 3 vaccine trial.

15,181

The number of Moderna phase 3 participants who received the vaccine, not a placebo.

2.9M

The number of Pfizer vaccine doses the U.S. government hoped to ship to medical workers in the vaccine’s first week of distribution.